Traws Pharma (TRAW) Competitors $1.65 -0.11 (-6.14%) As of 01:59 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW vs. MNOV, OKYO, TCRX, LFVN, and ENTXShould you buy Traws Pharma stock or one of its competitors? MarketBeat compares Traws Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Traws Pharma include MediciNova (MNOV), OKYO Pharma (OKYO), TScan Therapeutics (TCRX), Lifevantage (LFVN), and Entera Bio (ENTX). These companies are all part of the "pharmaceutical products" industry. TRAW vs. MNOVTRAW vs. OKYOTRAW vs. TCRXTRAW vs. LFVNTRAW vs. ENTXHow does Traws Pharma compare to MediciNova?Traws Pharma (NASDAQ:TRAW) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Does the media prefer TRAW or MNOV? In the previous week, Traws Pharma had 1 more articles in the media than MediciNova. MarketBeat recorded 2 mentions for Traws Pharma and 1 mentions for MediciNova. Traws Pharma's average media sentiment score of 1.50 equaled MediciNova'saverage media sentiment score. Company Overall Sentiment Traws Pharma Very Positive MediciNova Very Positive Which has preferable valuation and earnings, TRAW or MNOV? Traws Pharma has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$2.79M6.02$9.17M-$1.69N/AMediciNova$596.64K114.75-$12M-$0.23N/A Do analysts prefer TRAW or MNOV? Traws Pharma currently has a consensus target price of $8.00, indicating a potential upside of 384.26%. MediciNova has a consensus target price of $7.50, indicating a potential upside of 439.18%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.86 Which has more volatility and risk, TRAW or MNOV? Traws Pharma has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Is TRAW or MNOV more profitable? Traws Pharma has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Traws PharmaN/A -913.18% -133.88% MediciNova -1,962.98%-27.28%-25.24% Do insiders & institutionals hold more shares of TRAW or MNOV? 8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 14.0% of Traws Pharma shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryMediciNova beats Traws Pharma on 10 of the 16 factors compared between the two stocks.How does Traws Pharma compare to OKYO Pharma?Traws Pharma (NASDAQ:TRAW) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Which has stronger earnings & valuation, TRAW or OKYO? Traws Pharma has higher revenue and earnings than OKYO Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$2.79M6.02$9.17M-$1.69N/AOKYO PharmaN/AN/A-$4.71MN/AN/A Is TRAW or OKYO more profitable? OKYO Pharma's return on equity of 0.00% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Traws PharmaN/A -913.18% -133.88% OKYO Pharma N/A N/A N/A Do insiders and institutionals hold more shares of TRAW or OKYO? 8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 14.0% of Traws Pharma shares are owned by insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, TRAW or OKYO? Traws Pharma has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market. Do analysts prefer TRAW or OKYO? Traws Pharma presently has a consensus price target of $8.00, indicating a potential upside of 384.26%. OKYO Pharma has a consensus price target of $6.33, indicating a potential upside of 293.37%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Traws Pharma is more favorable than OKYO Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50OKYO Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Does the media favor TRAW or OKYO? In the previous week, OKYO Pharma had 1 more articles in the media than Traws Pharma. MarketBeat recorded 3 mentions for OKYO Pharma and 2 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.50 beat OKYO Pharma's score of 0.00 indicating that Traws Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive OKYO Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTraws Pharma beats OKYO Pharma on 8 of the 13 factors compared between the two stocks.How does Traws Pharma compare to TScan Therapeutics?TScan Therapeutics (NASDAQ:TCRX) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk. Does the media refer more to TCRX or TRAW? In the previous week, Traws Pharma had 2 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for Traws Pharma and 0 mentions for TScan Therapeutics. Traws Pharma's average media sentiment score of 1.50 beat TScan Therapeutics' score of 0.00 indicating that Traws Pharma is being referred to more favorably in the news media. Company Overall Sentiment TScan Therapeutics Neutral Traws Pharma Very Positive Which has preferable earnings & valuation, TCRX or TRAW? Traws Pharma has lower revenue, but higher earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTScan Therapeutics$9.14M7.02-$129.77M-$0.96N/ATraws Pharma$2.79M6.02$9.17M-$1.69N/A Do insiders & institutionals hold more shares of TCRX or TRAW? 82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 14.0% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate TCRX or TRAW? TScan Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 511.62%. Traws Pharma has a consensus target price of $8.00, suggesting a potential upside of 384.26%. Given TScan Therapeutics' higher possible upside, research analysts plainly believe TScan Therapeutics is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33Traws Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Is TCRX or TRAW more profitable? Traws Pharma has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. TScan Therapeutics' return on equity of -91.94% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets TScan Therapeutics-1,360.61% -91.94% -50.15% Traws Pharma N/A -913.18%-133.88% Which has more risk and volatility, TCRX or TRAW? TScan Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. SummaryTraws Pharma beats TScan Therapeutics on 9 of the 17 factors compared between the two stocks.How does Traws Pharma compare to Lifevantage?Traws Pharma (NASDAQ:TRAW) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations. Which has higher earnings and valuation, TRAW or LFVN? Lifevantage has higher revenue and earnings than Traws Pharma. Traws Pharma is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$2.79M6.02$9.17M-$1.69N/ALifevantage$228.53M0.30$9.81M$0.4512.00 Which has more risk and volatility, TRAW or LFVN? Traws Pharma has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Lifevantage has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Do analysts recommend TRAW or LFVN? Traws Pharma currently has a consensus target price of $8.00, suggesting a potential upside of 384.26%. Lifevantage has a consensus target price of $5.00, suggesting a potential downside of 7.41%. Given Traws Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Traws Pharma is more favorable than Lifevantage.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50Lifevantage 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is TRAW or LFVN more profitable? Lifevantage has a net margin of 2.94% compared to Traws Pharma's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Traws PharmaN/A -913.18% -133.88% Lifevantage 2.94%23.89%12.47% Do insiders and institutionals have more ownership in TRAW or LFVN? 8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 35.3% of Lifevantage shares are owned by institutional investors. 14.0% of Traws Pharma shares are owned by insiders. Comparatively, 22.0% of Lifevantage shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer TRAW or LFVN? In the previous week, Traws Pharma and Traws Pharma both had 2 articles in the media. Traws Pharma's average media sentiment score of 1.50 beat Lifevantage's score of -0.44 indicating that Traws Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lifevantage 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryLifevantage beats Traws Pharma on 9 of the 16 factors compared between the two stocks.How does Traws Pharma compare to Entera Bio?Entera Bio (NASDAQ:ENTX) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Do analysts rate ENTX or TRAW? Entera Bio currently has a consensus price target of $9.00, indicating a potential upside of 614.85%. Traws Pharma has a consensus price target of $8.00, indicating a potential upside of 384.26%. Given Entera Bio's higher probable upside, equities analysts clearly believe Entera Bio is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Traws Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Which has higher valuation & earnings, ENTX or TRAW? Traws Pharma has higher revenue and earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntera Bio$40K1,549.20-$11.44M-$0.27N/ATraws Pharma$2.79M6.02$9.17M-$1.69N/A Is ENTX or TRAW more profitable? Entera Bio's return on equity of -83.31% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Entera BioN/A -83.31% -70.83% Traws Pharma N/A -913.18%-133.88% Which has more volatility & risk, ENTX or TRAW? Entera Bio has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Do insiders & institutionals believe in ENTX or TRAW? 14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 10.4% of Entera Bio shares are owned by company insiders. Comparatively, 14.0% of Traws Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer ENTX or TRAW? In the previous week, Entera Bio had 2 more articles in the media than Traws Pharma. MarketBeat recorded 4 mentions for Entera Bio and 2 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.50 beat Entera Bio's score of 1.00 indicating that Traws Pharma is being referred to more favorably in the news media. Company Overall Sentiment Entera Bio Positive Traws Pharma Very Positive SummaryEntera Bio beats Traws Pharma on 8 of the 15 factors compared between the two stocks. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition ExportMetricTraws PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.81M$2.98B$6.28B$12.14BDividend YieldN/A1.98%2.80%5.32%P/E Ratio-0.9817.3020.6125.12Price / Sales6.02576.86581.1392.21Price / Cash2.4656.3527.4837.30Price / Book-23.603.919.746.62Net Income$9.17M$74.99M$3.55B$335.39M7 Day Performance-1.67%-4.48%-1.79%-1.72%1 Month Performance32.16%-8.02%-3.65%-1.61%1 Year Performance23.28%29.92%29.85%27.79% Traws Pharma Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma3.527 of 5 stars$1.65-6.1%$8.00+384.3%+47.9%$16.81M$2.79MN/A17Positive NewsEarnings ReportMNOVMediciNova2.8051 of 5 stars$1.37-0.7%$7.50+447.4%+5.3%$67.93M$410KN/A10Earnings ReportOKYOOKYO Pharma1.7199 of 5 stars$1.62flat$6.33+290.9%+7.4%$65.70MN/AN/A7News CoverageGap DownTCRXTScan Therapeutics3.3166 of 5 stars$1.16+0.9%$6.00+417.2%-19.4%$65.44M$10.32MN/A100LFVNLifevantage2.5916 of 5 stars$5.27+2.3%$5.00-5.1%-61.2%$64.97M$228.53M11.71260 Related Companies and Tools Related Companies MediciNova Competitors OKYO Pharma Competitors TScan Therapeutics Competitors Lifevantage Competitors Entera Bio Competitors ImageneBio Competitors Invizyne Technologies Competitors PDS Biotechnology Competitors MindWalk Competitors Lixte Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRAW) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
